Sperimentazione in fase di reclutamento = ; Sperimentazione in corso = ; Sperimentazione conclusa = ; Finanziato da un ente associato a IRDiRC = ; Membro di una ERN =

Sperimentazioni cliniche nazionali

FRANCIA

ILE-DE-FRANCE
PARIS

MYOMEX: Efficacy and Safety of Mexiletine in Non-dystrophic Myotonias (Phase III)

AP-HP.Sorbonne Université - Hôpital de la Pitié-Salpêtrière

Unité Neurogénétique et métabolisme

Ulteriori dettagli

PAESI BASSI

Gelderland
NIJMEGEN

Combining N-of-1 Trials to Estimate Population Clinical and Cost-effectiveness of Drugs Using Bayesian Hierarchical Modeling. The Case of Mexiletine for Patients With Non- Dystrophic Myotonia

Radboudumc - Radboud universitair medisch centrum

Afdeling Health Evidence

Ulteriori dettagli

PAESI BASSI

Gelderland
NIJMEGEN

Combining N-of-1 Trials to Estimate Population Clinical and Cost-effectiveness of Drugs Using Bayesian Hierarchical Modeling. The Case of Mexiletine for Patients With Non- Dystrophic Myotonia

Radboudumc - Radboud universitair medisch centrum

Afdeling Neurologie

Ulteriori dettagli

REGNO UNITO; GRAN BRETAGNA

Greater London
LONDON

A Phase II Randomised, Double-Blind, Placebo Controlled, Cross-Over Study to Investigate the Efficacy of Mexiletine in Patients with Non-Dystrophic Myotonia

National Hospital for Neurology and Neurosurgery

Department of Molecular Neuroscience

Ulteriori dettagli

STATI UNITI

New York
ROCHESTER

A Randomized, Placebo Controlled, Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type-1 (DM1) (Phase 2) - US

University of Rochester

Neurology, University of Rochester

Ulteriori dettagli